

Second Quarter 2026 Performance Summary

August 2026



TOTAL REVENUE

\$783 M -2% y/y¹



Tyvaso²

\$453M -4% y/y



Remodulin

\$126M -6% y/y



Orenitram

\$126M +1% y/y



Unituxin

\$65M +12% y/y



TTM OPERATING CASH FLOW

\$1.7 billion



CASH, CASH EQUIVALENTS, & MARKETABLE INVESTMENTS

\$3.8 billion

Quarterly Highlights



- Record Tyvaso DPI starts, referrals, commercial and total patients
- Most prescribed U.S. prostacyclin



- Most prescribed parenteral prostacyclin in the U.S.




- Eighteenth consecutive quarter of quarterly y/y revenue growth



- Most prescribed antibody therapy for high-risk neuroblastoma in the U.S.

Quarterly Revenue, millions USD



NASDAQ

UTHR

2025 Financials

PRODUCT REVENUE

~\$3.2 billion

REVENUE/EMPLOYEE

~\$2.3 million

FOUNDED

1996

HQ

**Research Triangle Park, NC
Silver Spring, MD**

EMPLOYEES

>1,400⁴

1. y/y = year over year. 2. Tyvaso DPI + Nebulized Tyvaso. 3. CAGR = compound annual growth rate calculated from 2Q/21 to 2Q/26. 4. As of 12/31/2025.

Pipeline

Development Engine Addressing Unmet Needs

	Non-Registration	Registration	Filed	Approved
--	------------------	--------------	-------	----------

Drugs & Devices

TETON-1 & 2 - Nebulized Tyvaso® - Idiopathic Pulmonary Fibrosis
TETON-PPF - Nebulized Tyvaso® - Progressive Pulmonary Fibrosis
SUMMIT - Pulmonary Hypertension Associated with COPD¹
Treprostinil SMI - PAH/PH-ILD/PH-COPD³/IPF/PPF
Treprostinil-Iloprost - SMI PRN¹⁰ - PAH²
ADVANCE OUTCOMES - Ralinepag - PAH
Ralinepag DPI - PAH/PH-ILD/IPF/PPF
Ralinepag Triple Combination⁹ - PAH

Xeno, Organs, and Organ Alternatives

EVLP³/CLES⁴ - Lung Transplant
EXPAND - UKidney™ - End Stage Renal Disease⁵
EXTEND - UThymoKidney™ - End Stage Renal Disease⁵
EXPRESS - UHeart™ - Advanced Heart Failure⁵
miroliverELAP⁶ - Acute Liver Failure

Pre-clinical Xeno and Organ Alternative Programs

ULung™ - End Stage Lung Disease	miroliver® - End Stage Liver Disease	mirokidney® - End Stage Renal Disease
IVIVA Kidney - End Stage Renal Disease	ULobe™ - End Stage Lung Disease	THY-100 - Congenital Asthymia

Pipeline Spotlights

AQUISITION Thymune Therapeutics	UHEART™ EXPRESS Cleared to Proceed	NEW DEVICES Treprostinil SMI and Ralinepag DPI
--	---	---

How We Operate

CURRENT COMMERCIAL PORTFOLIO	DRUG/ DEVICE PIPELINE	ORGAN PIPELINE
Tyvaso DPI (PAH & PH-ILD) Nebulized Tyvaso (PAH & PH-ILD) Orenitram (PAH) Remodulin (PAH) Unituxin (Neuroblastoma) EVLP (Lung Transplant)	Tyvaso DPI (IPF & PPF) Treprostinil SMI⁷ (PAH, PH-ILD, PH-COPD⁸, IPF & PPF) Nebulized Tyvaso (IPF & PPF) Ralinepag Tablets (PAH) Ralinepag DPI (PAH, PH-ILD, IPF & PPF) Ralinepag Triple Combo (PAH) Treprostinil-Iloprost SMI PRN (PAH)	Xenotransplantation (UKidney, UThymoKidney, Uheart) Autologous Regenerative Medicine (ULung, IVIVA Kidney) Allogeneic Regenerative Medicine (miroliverELAP, miroliver, mirokidney, ULobe) Thymic Immune Restoration (THY-100)

This Fact Sheet contains forward-looking statements that are subject to risks and uncertainties, which are described in greater detail at ir.unither.com/disclaimer

1. COPD = chronic obstructive pulmonary disease. 2. PAH = pulmonary arterial hypertension. 3. EVLP = ex-vivo lung perfusion. 4. CLES = centralized lung evaluation system. 5. Registrational status pending agreement with the FDA. 6. ELAP = external liver assist product. 7. SMI = soft mist inhaler. 8. PH-COPD = pulmonary hypertension associated with chronic obstructive pulmonary disease. 9. Triple combination consists of ralinepag + ERA + PDE5i 10. PRN = pro re nata ("as-needed")

Learn More



United Therapeutics' Corporate Website



United Therapeutics' Investor Relations Website



United Therapeutics' LinkedIn



United Therapeutics' Corporate Responsibility Website